Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis.

Study summary

Main finding

Thymosin beta4 combined with ciprofloxacin improved measured corneal disease outcomes compared with the control and single-agent groups, alongside changes in inflammation and wound-healing markers.

Read the full abstract & conclusion

What was studied: Mouse bacterial keratitis model
How the study was set up: An experimental bacterial keratitis model compared full-length thymosin beta4 plus ciprofloxacin with each intervention alone and a vehicle control.
What the researchers measured: Clinical eye scores, slit-lamp images, tissue appearance, bacterial burden, inflammatory cells, cytokines, and oxidative-stress markers were assessed.
How to read this evidence: Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.

Results in context

The combination performed differently from either component alone. It does not establish that thymosin beta4 can replace antibiotics or that a TB-500 preparation has the same effects.

What this does not establish

This was topical combination treatment in infected mouse corneas, not a TB-500 human trial. Effects cannot be assigned to commercial TB-500 or generalized to other routes or injuries.

This collection includes related thymosin beta4 research. Parent or engineered peptide findings do not establish that a TB-500 fragment or a product sold under that name has the same effects.

Publication & source

Why this paper is included: The title focuses on thymosin beta4 or TB-500; parent-peptide findings do not establish TB-500 fragment effects.
Publication indexing: Journal Article
Source checked: October 4, 2026. Years follow journal issues; online-first dates may differ.

Open PubMed record PMID 30241380 · Journal and full-text links

Educational research information. A publication does not verify the identity, quality, or safety of products sold here.

Back to TB-500 studies